European School of Robotic Stereotactic Radiotherapy Advances With the CyberKnife® M6(TM) System

SUNNYVALE, California, November 26, 2015 /PRNewswire/ --

Erasmus MC Team Hosts Clinicians from Around-the-World at Fully-Subscribed Course

Accuray Incorporated announced the second course of the European School of Robotic Stereotactic Radiotherapy at Erasmus MC Center Institute, Rotterdam, The Netherlands, following the course's successful inauguration in June 2015. The objectives of this School are to:

- Increase awareness of stereotactic body radiation therapy (SBRT) among the
radiation oncology and medical physics communities;
- Share SBRT knowledge and real-world experience using the CyberKnife(R) M6(TM) System;
- Facilitate CyberKnife use for new applications with experienced users.

(Logo: )

(Photo: )

"Erasmus MC Cancer Institute has a long history with Accuray. Working together, we are helping to change the way that cancer is treated," said Dr. Joost Nuyttens, M.D., Ph.D., Radiation Oncologist at Erasmus MC Cancer Institute. "Our Center's extensive technical research and clinical experience with the CyberKnife System have enabled us to experience first-hand the benefits that stereotactic radiotherapy offers to cancer patients. Accuray's support of the School enabled us to share our knowledge with clinicians worldwide through a peer-to-peer forum."

"Stereotactic" in Greek means "movement in space" and refers to 3D workspace to locate the tumor or target of a radiation dose. SBRT precisely targets the tumor to receive a maximum amount of radiation while sparing surrounding healthy tissue from radiation exposure. SBRT is a non-invasive treatment that does not require surgery and reduces the risks of complications sometimes associated with conventional surgery.

Accuray has been working with Erasmus MC Cancer Institute since the Center installed its first CyberKnife System in 2004. The Center was the third site in the EIMEA (Europe, India, Middle East, and Africa) region to install a CyberKnife System. To date, more than 2,000 patients, including those with brain, spine, lung, liver, and prostate cancer have been treated with the two CyberKnife Systems at Erasmus MC.

"Erasmus MC Cancer Institute has reported an expected growth of 21% for SBRT treatment volume between 2012 to 20171. As one of the world's foremost academic oncology centers, this Institute is an important partner for us in advancing the use of SBRT," said Lionel Hadjadjeba, senior vice president, and president, worldwide commercial operations at Accuray. "The European School will contribute to improve the understanding of the added clinical value of robotic stereotactic radiotherapy using the CyberKnife System. With the support of hospitals like Erasmus MC Cancer Institute, Accuray is offering precise, innovative radiation oncology treatments to more cancer patients".

1Reference: (c)2013 The Advisory Board Company, Hospital Outpatient Department   

About Erasmus MC Cancer Institute   

Erasmus MC is one of the largest and most authoritative scientific University Medical Centers in the Netherlands. 11,250 staff members, including almost 1,400 students, work within the core tasks of patient care, education, and scientific research on the continuous improvement and enforcement of individual patient care and social healthcare. They develop high-level knowledge, pass this on to future professionals, and apply it in everyday patient care. Over the next five years, Erasmus MC aims to grow into one of the leading international medical institutes. Erasmus MC is part of the Dutch Federation of University Medical Centers (NFU).

About Accuray   

Accuray Incorporated is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments.

Safe Harbor Statement   

Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to market awareness, education, adoption and acceptance, clinical results, patient outcomes and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 28, 2015, the company's report on Form 10-Q, filed on November 5, 2015, and the company's other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.


Accuray Incorporated

CONTACT: Contact: Sancie Nakarat, Director, Marketing Communication, Tél+33-06-8136-84-34,

PR Newswire

Dit persbericht is via ANP Pers Support naar internationale (vak en online) media gestuurd. Heb je nieuws voor buitenlandse journalisten? Bekijk dan onze mogelijkheden of neem contact met ons op.

Verstuur nu éénmalig een persbericht

Verstuur persberichten en beeldmateriaal naar redacties in binnen- en buitenland. Via het ANP-net, het internationale medianetwerk van PR Newswire of met een perslijst op maat.

Direct persbericht versturen
070 - 41 41 234